[1] Ackermann H. (1991): BIAS - A programme package for biometrical analysis of samples., Comp.Stat. 11, Seite 223-224.

[2] AizawaY.; Fukatsu R.; Takamaru Y.; Tsuzuki K.; Chiba H.; Kobayashi K.; Fujii N. und Takahata N. (1997): Amino-terminus truncated apolipoprotein E is the major species in amyloid deposits in Alzheimer's disease-affected brains: a possible role for apolipoprotein E in Alzheimer's disease, Brain Res. 768 [1-2], Seite 208-214.

[3] Alzheimer, A. (1907): Über eine eigenartige Erkrankung der Hirnrinde, Centralblatt für Nervenheilkunde und Psychiatrie., Seite 177-179.

[4] Arendt T.; Schindler C.; Brückner M.K.; Eschrich K.; Bigl V.; Zedlick D. und Markova L. (1997): Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein e4 allele., J Neurosci 17 [2], Seite 516-529.

[5] Arendt, T.; Bruckner, M. K.; Gertz, H. J. und Marcova, L. (1998): Cortical distribution of neurofibrillary tangles in Alzheimer's disease matches the pattern of neurons that retain their capacity of plastic remodelling in the adult brain, Neuroscience 83 [4], Seite 991-1002.

[6] Balbin, M.; Freije, J. M.; Fueyo, A.; Sanchez, L. M. und Lopez-Otin, C. (1990): Apolipoprotein D is the major protein component in cyst fluid from women with human breast gross cystic disease, Biochem J 271 [3], Seite 803-807.

[7] Bancher, C.; Jellinger, K.; Lassmann, H.; Fischer, P. und Leblhuber, F. (1996): Correlations between mental state and quantitative neuropathology in the Vienna Longitudinal Study on Dementia, Eur.Arch.Psychiatry Clin.Neurosci. 246 [3], Seite 137-146.

[8] Bao, F.; Arai, H.; Matsushita, S.; Higuchi, S. und Sasaki, H. (1996): Expression of apolipoprotein E in normal and diverse neurodegenerative disease brain, Neuroreport. 7 [11], Seite 1733-1739.

[9] Barger S.W. und Harmon A.D. (1997): Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E, Nature 388 [6645], Seite 878-881.

[10] Bazan, N. G.; Colangelo, V. und Lukiw, W. J. (2002): Prostaglandins and other lipid mediators in Alzheimer's disease, Prostaglandins Other Lipid Mediat. 68-69, Seite 197-210.

[11] Beal, M. F. (1995): Aging, energy, and oxidative stress in neurodegenerative diseases, Ann.Neurol. 38 [3], Seite 357-366.

[12] Beffert U.; Cohn J.S.; Petit Turcotte C.; Tremblay M.; Aumont N.; Ramassamy C.; Davignon J. und Poirier J. (1999): Apolipoprotein E and beta-amyloid levels in the hippocampus and frontal cortex of Alzheimer's disease subjects are disease- related and apolipoprotein E genotype dependent, Brain Res. 843 [1-2], Seite 87-94.

[13] Beffert U. und Poirier J. (1996): Apolipoprotein E, plaques, tangles and cholinergic dysfunction in Alzheimer's disease, Ann.N.Y.Acad.Sci. 777, Seite 166-174.

[14] Belloir, B.; Kövari, E.; Surini-Demiri, M. und and Savioz, A (2001): Altered apolipoprotein D expression in the brain of patients with Alzheimer disease, J Neurosci Res 64, Seite 61-69.

[15] Bellosta S.Nathan B.P.; Orth M.; Dong L.M.; Mahley R.W. und Pitas R.E. (1995): Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neurite outgrowth, J Biol.Chem. 270 [45], Seite 27063-27071.

[16] Benzing, W. C. und Mufson, E. J. (1995): Apolipoprotein E immunoreactivity within neurofibrillary tangles: relationship to Tau and PHF in Alzheimer's disease, Exp.Neurol. 132 [2], Seite 162-171.

[17] Bertrand P.; Poirier J.; Oda T.; Finch C.E. und Pasinetti G.M. (1995): Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease, Brain Res Mol.Brain Res 33 [1], Seite 174-178.

[18] Beyreuther, K. und Masters CL (1990): Nomenclature of Amyloid A4 Proteins and Their Precursors in Alzheimers Disease and Downs Syndrome, Neurobiol Aging. 11, Seite 66-68.

[19] Bickel, H. (2000): Demenzsyndrom und Alzheimer Krankheit: Eine Schatzung des Krankenbestandes und der jahrlichen Neuerkrankungen in Deutschland. [Dementia syndrome and Alzheimer disease: an assessment of morbidity and annual incidence in Germany], Gesundheitswesen 62 [4], Seite 211-218.

[20] Blanco Vaca, F.; Via, D. P.; Yang, C. Y.; Massey, J. B. und Pownall, H. J. (1992): Characterization of disulfide-linked heterodimers containing apolipoprotein D in human plasma lipoproteins, J.Lipid Res. 33 [12], Seite 1785-1796.

[21] Boschert, U.; Merlo Pich, E.; Higgins, G.; Roses, A. D. und Catsicas, S. (1999): Apolipoprotein E expression by neurons surviving excitotoxic stress, Neurobiol.Dis. 6 [6], Seite 508-514.

[22] Boyles, J. K.; Notterpek, L. M. und Anderson, L. J. (1990): Accumulation of apolipoproteins in the regenerating and remyelinating mammalian peripheral nerve. Identification of apolipoprotein D, apolipoprotein A-IV, apolipoprotein E, and apolipoprotein A-I, J.Biol.Chem. 265 [29], Seite 17805-17815.

[23] Boyles, J. K.; Pitas, R. E.; Wilson, E.; Mahley, R. W. und Taylor, J. M. (1985): Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system, J.Clin.Invest. 76 [4], Seite 1501-1513.

[24] Braak, H. und Braak, E. (1991): Neuropathological stageing of Alzheimer-related changes, Acta Neuropathol.Berl 82 [4], Seite 239-259.

[25] Braak, H. und Braak, E. (1996): Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis, Acta Neuropathol Berl 92 [2], Seite 197-201.

[26] Braak, H.; Duyckaerts, C.; Braak, E. und Piette, F. (1993): Neuropathological stageing of Alzheimer related changes correlates with psychometrically assessed intellectual status, Alzheimer's Disease: Advances in Clinical and Basic Research, Seite 131-137.

[27] Bullido, M. J. und Valdivieso, F. (2000): Apolipoprotein E gene promoter polymorphisms in Alzheimer's disease, Microscopy Res Tech 50, Seite 261-267.

[28] Cedazo-Minguez, A.; Hamker, U.; Veh, R.; Meske, V.; Albert, F.; Cowburn, R. F. und and Ohm, T. G. (2001): Regulation of apolipoprotein E secretion in rat primary hippocampal astrocyte cultures, Neurosci 105(3), Seite 651-661.

[29] Colton, C. A.; Brown, C. M. und Cook, D. (2002): ApoE and the regulation of microglial nitric oxide production: a link between genetic risk and oxidative stress, Neurobiol Aging 23, Seite 777-785.

[30] Corder, E. H.; Saunders, A. M.; Strittmatter, W. J.; Schmechel, D. E.; Gaskell, P. C.; Rimmler, J. B.; Locke, P. A.; Conneally, P. M.; Schmader, K. E.; Tanzi, R. E.; Gusella, J. F.; Small, G. W.; Roses, A. D.; Pericak Vance, M. A. und Haines, J. L. (1995): Apolipoproein E, survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease., Neurology. 45 [7], Seite 1323-1328.

[31] del Valle, E.; Navarro, A.; Astudillo, A. und Tolivia, J. (2003): Apolipoprotein D expression in human brain reactive astrocytes, J Histochem Cytochem 51 [10], Seite 1285-1290.

[32] Desai, P. P.; Hendrie, H. C.; Evans, R. M.; Murrell, J. R.; Dekosky, S. T. und Kamboh, M. I. (2003): Genetic variation in apolipoprotein D affects the risk of Alzheimer disease in african-americans, Am J Med Genet 116B, Seite 98-101.

[33] Dickson, D. W.; Sinicropi, S.; Yen, S. H.; Ko, L. W.; Mattiace, L. A.; Bucala, R. und Vlassara, H. (1996): Glycation and microglial reaction in lesions of Alzheimer's disease, Neurobiol Aging 17 [5], Seite 733-743.

[34] Diedrich, J. F.; Minnigan, H.; Carp, R. I.; Whitaker, J. N.; Race, R.; Frey, W. 2d und Haase, A. T. (1991): Neuropathological changes in scrapie and Alzheimer's disease are associated with increased expression of apolipoprotein E and cathepsin D in astrocytes, J.Virol. 65 [9], Seite 4759-4768.

[35] Drayna, D.; Fielding, C.; Mclean, J.; Baer, B.; Castro, G.; Chen, E.; Comstock, L.; Henzel, W.; Kohr, W.; Rhee, L. und et al (1986): Cloning and expression of human apolipoprotein D cDNA, J.Biol.Chem. 261 [35], Seite 16535-16539.

[36] Fielding, P. E. und Fielding, C. J. (1980): A cholesteryl ester transfer complex in human plasma, Proc Natl Acad Sci U.S.A 77 [6], Seite 3327-3330.

[37] Fleming, L. M.; Weisgraber, K. H.; Strittmatter, W. J.; Troncoso, J. C. und Johnson, G. V. (2001): Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins, Exp Neurol 138, Seite 252-260.

[38] Flood DG; Buell, S. J.; Horwitz GJ und Coleman PD (1987): Dendritic extent in human dentate gyrus granule cells in normal aging and senile dementia, Brain Res. 402, Seite 205-216.

[39] Flood, D. G.; Buell, S. J.; Defiore, C. H.; Horwitz, G. J. und Coleman, P. D. (1985): Age-related dendritic growth in dentate gyrus of human brain is followed by regression in the 'oldest old', Brain Res. 345 [2], Seite 366-368.

[40] Flower, D. R. (1996): The lipocalin protein family: structure and function, Biochem.J. 318 [Pt 1], Seite 1-14.

[41] Francone, O. L.; Gurakar, A. und Fielding, C. (1989): Distribution and functions of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in plasma lipoproteins. Evidence for a functional unit containing these activities together with apolipoproteins A-I and D that catalyzes the esterification and transfer of cell-derived cholesterol, J Biol Chem 264 [12], Seite 7066-7072.

[42] Franz, G.; Reindl, M.; Patel, S. C.; Beer, R.; Unterrichter, I.; Berger, T.; Schmutzhard, E.; Poewe, W. und Kampfl, A. (1999): Increased expression of apolipoprotein D following experimental traumatic brain injury, J.Neurochem. 73 [4], Seite 1615-1625.

[43] Gearing, M.; Schneider, J. A.; Robbins, R. S.; Hollister, R. D.; Mori, H.; Games, D; Hyman, B. T. und Mirra, S. S. (1995): Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer's disease, J Neuropathol.Exp.Neurol. 54 [6], Seite 833-841.

[44] Gerdes, L. U.; Jeune, B.; Ranberg, K. A.; Nybo, H. und Vaupel, J. W. (2000): Estimation of apolipoprotein E genotype-specific relative mortality risks from the distribution of genotypes in centenarians and middle-aged men: apolipoproten E gene is a "frailty gene" not a "longevity gene", Genet Epidemiol 19, Seite 202-210.

[45] Goedert, M.; Wischik, C. M.; Crowther, R. A.; Walker, J. E. und Klug, A. (1988): Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau, Proc.Natl.Acad.Sci.U.S.A. 85 [11], Seite 4051-4055.

[46] Goessling, W. und Zucker, S. D. (2000): Role of apolipoprotein D in the transport of bilirubin in plasma, Am J Physiol Gastrointest.Liver Physiol 279 [2], Seite G356-G365.

[47] Gomez-Ramos, P.; Mufson, E. J. und Moran, M. A. (2001): Apolipoprotein E immunoreactivity in neurons and neurofibrillary degeneration of aged non-demented and Alzheimer's disease patients, Microsc.Res Tech 55 [1], Seite 48-58.

[48] Gouras, G. K.; Tsai, J.; Naslund, J.; Vincent, B.; Edgar, M.; Checler, F.; Greenfield, J. P.; Haroutunian, V.; Buxbaum, J. D.; Xu, H.; Greengard, P. und Relkin, N. R. (2000): Intraneuronal Abeta42 accumulation in human brain, Am J Pathol 156 [1], Seite 15-20.

[49] Haagensen, D. E. und and Mazoujian, G. (1986): Biochemistry and Immunohistochemistry o fluid proteins of the breast in gross cystic disease, C.D.Haagensen (Ed.), Diseases of the breast, 3rd edn. , Seite 500, Saunders,

[50] Han, S. H.; EInstein, G.; Weisgraber, K. H.; Strittmatter, W. J.; Saunders, A. M.; Pericak Vance, M.; Roses, A. D. und Schmechel, D. E. (1994): Apolipoprotein E is localized to the cytoplasm of human cortical neurons: a light and electron microscopic study, J.Neuropathol.Exp.Neurol. 53 [5], Seite 535-544.

[51] Han, S. H.; Hulette, C.; Saunders, A. M.; EInstein, G.; Pericak-Vance, M.; Strittmatter, W. J.; Roses, A. D. und Schmechel, D. E. (1994): Apolipoprotein E Is Present in Hippocampal Neurons without Neurofibrillary Tangles in Alzheimer's Disease and in Age-Matched Controls, Experimental Neurology. [128], Seite 13-26.

[52] Harr, S. D.; Uint, L.; Hollister, R.; Hyman, B. T. und Mendez, A. J. (1996): Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease, J.Neurochem. 66 [6], Seite 2429-2435.

[53] Hayashi, S.; Wakabayashi, K.; Iwanaga, K.; Kakita, A.; Seki, K.; Tanaka, M; Okuizumi, K.; Onodera, O.; Tanaka, H.; Tsuji, S. und Takahashi, H. (1998): Pick's disease: selective occurrence of apolipoprotein E-immunoreactive Pick bodies in the limbic system, Acta Neuropathol (Berl) 95 [1], Seite 1-4.

[54] Helisalmi, S.; Hiltunen, M.; Vepsalainen, S.; Iivonen, S.; Corder, E. H.; Lehtovirta, M.; Mannermaa, A.; Koivisto, A. M. und Soininen, H. (2004): Genetic variation in apolipoprotein D and Alzheimer's disease, J Neurol 251 [8], Seite 951-957.

[55] Hesse, C.; Bogdanovic, N.; Davidsson, P. und Blennow, K. (1999): A quantitative and immunhistochemical study on apolipoprotein E in brain tissue in Alzheimer's disease, Dement Geriatr Cogn Disord 10, Seite 452-459.

[56] Holzfeind, P.; Merschak, P.; Dieplinger, H. und Redl, B. (1995): The human lacrimal gland synthesizes apolipoprotein D mRNA in addition to tear prealbumin mRNA, both species encoding members of the lipocalin superfamily, Exp.Eye Res. 61 [4], Seite 495-500.

[57] Horrobin, D. F. und and Bennett, C. N. (1999): New gene targets related to schizophrenia and other psychiatric disorders: enzymes, binding proteins and transport proteins involved in phospholipid and fatty acid metabolism, Prostaglandins, Leukotrienes and Essential Fatty Acids 60, Seite 141-167.

[58] Huang, D. Y.; Weisgraber, K. H.; Goedert, M.; Saunders, A. M.; Roses, A. D. und Strittmatter, W. J. (1995): ApoE3 binding to tau tandem repeat I is abolished by tau serine262 phosphorylation, Neurosci.Lett. 192 [3], Seite 209-212.

[59] Hyman, B. T.; van Hoesen, G. W.; Damasio, A. R. und Barnes, C. L. (1984): Alzheimer's disease: Cell-specific pathology isolates the hippocampal formation, Science. 225, Seite 1168-1170.

[60] Ikonomovic, M. D.; Desai, P. P.; Kamboh, M. I. Hamilton R. L.; Klunk, W. E. und Dekosky, S. T. (2002): Apolipoprotein D and beta-amyloid in progression of neuritic plaques: a study of Alzheimer's disease and lewy body variant, Neubiol Aging 23 [1S], Seite S 394.

[61] Jian-Gang, Z.; Yong-Xing, M.; Chuan-Fu, W.; Pei-Fang, L.; Song-Bai, Z.; Nui-Fan, G.; Guo-Yin, F. und Lin, H. (1998): Apolipoprotein E and longevity among Han Chinese population, Mech Ageing Dev 104, Seite 159-167.

[62] Jolivalt, C.; Leininger-Muller, B.; Bertrand, P.; Herber, R.; Christen, Y. und Siest, G. (2000): Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids, Free Radic.Biol Med 28 [1], Seite 129-140.

[63] Kalman, J.; McConathy, W.; Araoz, C.; Kasa, P. und Lacko, A. G. (2000): Apolipoprotein D in the aging brain and in Alzheimer's dementia, Neurol.Res. 22 [4], Seite 330-336.

[64] Kang J; Lemaire HG; Unterbeck A; Salbaum JM; Masters CL; Grzeschik KH; Multhaup G; Beyreuther, K. und Müller-Hill B (1987): The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor, Nature. 325, Seite 733-736.

[65] Kesner, L.; Yu, W. S.; Bradlow, H. L.; Breed, C. W. und Fleisher, M. (1988): Proteases in cyst fluid from human gross cyst breast disease, Cancer Res 48 [22], Seite 6379-6383.

[66] Kida, E.; Golabek, A. A.; Wisniewski, T. und Wisniewski, K. E. (1994): Regional differences in apolipoprotein E immunoreactivity in diffuse plaques in Alzheimer's disease brain, Neurosci.Lett. 167 [1-2], Seite 73-76.

[67] Kim, K. W.; Jhoo, J. H.; Lee, J. H.; Lee, D. Y.; Lee, K. U.; Youn, J. C.; Youn, J. Y. und Woo, J. I. (2002): The domain-specific, stage-limited impact of the apolipoprotein E epsilon-4 allele on cognitive functions in Alzheimer's disease, Dement Geriatr Cogn Disord 13 [3], Seite 125-129.

[68] Kimpara, T.; Takeda, A.; Yamaguchi, T.; Arai, H.; Okita, N.; Takase, S.; Sasaki, H. und Itoyama, Y. (2000): Increased bilirubins and their derivatives in cerebrospinal fluid in Alzheimer's disease, Neurobiol Aging 21 [4], Seite 551-554.

[69] LaDu, M. J.; Falduto, M. T.; Manelli, A. M.; Reardon, C. A.; Getz, G. S. und Frail, D. E. (1994): Isoform-specific binding of apolipoprotein E to beta-amyloid, J Biol.Chem. 269 [38], Seite 23403-23406.

[70] LaDu, M. J.; Shah, J. A.; Reardon, C. A.; Getz, G. S.; Bu, G.; Hu, J.; Guo, L. und Van Eldik, L. J. (2000): Apolipoprotein E receptors mediate the effects of beta-amyloid on astrocyte cultures, J Biol Chem 275 [43], Seite 33974-33980.

[71] Laemmli, U. K. (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4, Nature 227 [259], Seite 680-685.

[72] Laskowitz, D. T.; Horsburgh, K. und Roses, A. D. (1998): Apolipoprotein E and the CNS response to injury, J.Cereb.Blood Flow Metab. 18 [5], Seite 465-471.

[73] Laws, S. M.; Hone, E.; Taddei, K.; Harper, C.; Dean, B; McClean, C.; Masters, C.; Lautenschlager, N.; Gandy, S. E. und Martins, R. N. (2002): Variation at the apoe-491 promoter locus is associated with altered brain levels of apolipoprotein E, Molec Psych 7 [8], Seite 886-890.

[74] Lea, O. A. (1988): Binding properties of progesterone-binding Cyst protein, PBCP, Steroids 52 [4], Seite 337-338.

[75] Liberski, P. P. und Budka, H. (1999): Neuroaxonal pathology in Creutzfeldt-Jakob disease, Acta Neuropathol (Berl) 97 [4], Seite 329-334.

[76] Lue, L. F.; Kuo, Y. M.; Roher, A. E.; Brachova, L.; Shen, Y.; Sue, L.; Beach, T.; Kurth, J. H.; Rydel, R. E. und Rogers, J. (1999): Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease, Am J Pathol 155 [3], Seite 853-862.

[77] Masliah, E.; Mallory, M.; Veinbergs, I.; Miller, A. und Samuel, W. (1996): Alterations in apolipoprotein E expression during aging and neurodegeneration, Prog.Neurobiol 50 [5-6], Seite 493-503.

[78] Maurer, K.; Ihl, R. und Frölich, L. (1993): Alzheimer: Grundlagen, Diagnostik, Therapie, Springer,

[79] Mayeux, R.; Ottman, R.; Maestre, G.; Ngai, C.; Tang, M. X.; Ginsberg, H.; Chun- M; Tycko, B. und Shelanski, M. (1995): Synergistic effects of traumatic head injury and apolipoprotein-epsilon 4 in patients with Alzheimer's disease [ see comments], Neurology 45 [3 Pt 1], Seite 555-557.

[80] McConathy, W. J. und Alaupovic, P. (1973): Isolation and partial characterization of apolipoprotein D: a new protein moiety of the human plasma lipoprotein system, FEBS Lett 37 [2], Seite 178-182.

[81] Meske, V.; Hamker, U.; Albert, F. und Ohm, T. G. (1998): The effects of beta /A4-amyloid and its fragments on calcium homeostasis, glial fibrillary acidic protein and S100 beta staining, morphology and survival of cultured hippocampal astrocytes, Neuroscience 85 [4], Seite 1151-1160.

[82] Metzger, R. E.; LaDu, M. J.; Pan, J. B.; Getz, G. S.; Frail, D. E. und Falduto, M. T. (1996): Neurons of the human frontal cortex display apolipoprotein E immunoreactivity: implications for Alzheimer's disease, J Neuropathol Exp Neurol 55 [3], Seite 372-380.

[83] Miehe, U.; Leranth, C.; Ohm, T. G. und Nitsch, R. (1994): Long-lasting transneuronal dendritic changes of GABAergic neurons in the monkey dentate gyrus following entorhinal cortex lesion, Neurosci.Lett 168 [1-2], Seite 115-118.

[84] Miller, A.; Alford, M.; Katzman, R.; Thal, L.; Saitoh, T. und Masliah, E. (1994): The expression of the APO-epsilon4 allele in Alzheimer's disease accentuates the synaptic loss and the severity of the dementia, Ann Neurol 36, Seite 268.

[85] Miyata, M. und Smith, J. D. (1996): Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides, Nat Genet 14 [1], Seite 55-61.

[86] Montine, K. S.; Olson, S. J.; Amarnath, V.; Whetsell, W. O., Jr.; Graham, D. G. und Montine, T. J. (1997): Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4, Am.J.Pathol. 150 [2], Seite 437-443.

[87] Montpied, P.; de Bock, F.; Lerner Natoli, M.; Bockaert, J. und Rondouin, G. (1999): Hippocampal alterations of apolipoprotein E and D mRNA levels in vivo and in vitro following kainate excitotoxicity, Epilepsy Res. 35 [2], Seite 135-146.

[88] Morais Cabral, J. H.; Atkins, G. L.; Sanchez, L. M.; Lopez Boado, Y. S.; Lopez, Otin-C und Sawyer, L. (1995): Arachidonic acid binds to apolipoprotein D: implications for the protein's function, FEBS Lett. 366 [1], Seite 53-56.

[89] Mukaetova-Ladinska, E. B.; Garcia-Siera, R.; Hurt, J.; Gertz, H. J.; Xuereb, J. H.; Hills, R.; Brayne, C.; Huppert, F. A.; Paykel, E. S.; McGee, M.; Jakes, R.; G.Honer, W.; Harrington, C. R. und Wischik, C. M. (2000): Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease, Am J Pathol 157, Seite 623-636.

[90] Müller, W.; Meske, V.; Berlin, K.; Scharnagl, H.; Marz, W. und Ohm, T. G. (1998): Apolipoprotein E isoforms increase intracellular Ca2+ differentially through a omega-agatoxin IVa-sensitive Ca2+-channel, Brain Pathol. 8 [4], Seite 641-653.

[91] Namba, Y.; Tomonaga, M.; Kawasaki, H.; Otomo, E. und Ikeda, K. (1991): Apolipoprotein-E Immunoreactivity in Cerebral Amyloid Deposits and Neurofibrillary Tangles in Alzheimer's Disease and Kuru Plaque Amyloid in Creutzfeldt-Jakob Disease, Brain Research. 541, Seite 163-166.

[92] Nathan, B. P.; Bellosta, S.; Sanan, D. A.; Weisgraber, K. H.; Mahley, R. W. und Pitas, RE (1994): Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro, Science 264 [5160], Seite 850-852.

[93] Nathan, B. P.; Chang, K. C.; Bellosta, S.; Brisch, E.; Ge, N.; Mahley, R. W. und Pitas, R. E. (1995): The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microtubule depolymerization, J.Biol.Chem. 270 [34], Seite 19791-19799.

[94] Nilsson, L. G.; Nyberg, L. und Backman, L. (2002): Genetic variation in memory functioning, Neurosci Biobehav Rev 26 [7], Seite 841-848.

[95] Nishiyama, E.; Iwamoto, N.; Ohwada, J. und Arai, H. (1997): Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope, Brain Res 750 [1-2], Seite 20-24.

[96] Nitsch, R. (1993): Transneuronal changes in the lesioned entorhinal-hippocampal system, Nitsch, R. und Ohm, T. G., Hippocampus , 3 Spec No. Auflage, Seite 247-256, Churchill Livingstone,

[97] Nunomura, A.; Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, E. K.; Jones, P. K.; Ghanbari, H.; Wataya, T.; Shimohama, S.; Chiba, S.; Atwood, C-S; Petersen, R. B. und Smith, M. A. (2001): Oxidative damage is the earliest event in Alzheimer disease, J Neuropathol Exp Neurol 60 [8], Seite 759-767.

[98] Ohm, T. G.; Müller, H.; Braak, H. und Bohl, J. (1995): Close-meshed prevalence rates of different stages as a tool to uncover the rate of Alzheimer's disease-related neurofibrillary changes, Neuroscience 64 [1], Seite 209-217.

[99] Ohm, T. G.; Münch, S.; Schönheit, B.; Zarski, R. und Nitsch, R. (2002): Transneuronally altered dendritic processing of tangle-free neurons in Alzheimer's disease, Acta Neuropathol 103, Seite 437-443.

[100] Ohm, T. G.; Scharnagl, H.; März, W. und Bohl, J. (1999): Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions, Acta Neuropathol.Berl. 98 [3], Seite 273-280.

[101] Ong, W. Y.; He, Y.; Suresh, S. und Patel, S. C. (1997): Differential expression of apolipoprotein D and apolipoprotein E in the kainic acid-lesioned rat hippocampus, Neuroscience 79 [2], Seite 359-367.

[102] Pearlman, W. H.; Gueriguian, J. L. und Sawyer, M. E. (1973): A specific progesterone-binding component of human breast cyst fluid, J Biol Chem 248 [16], Seite 5736-5741.

[103] Peitsch, M. C. und Boguski, M. S. (1990): Is apolipoprotein D a mammalian bilin-binding protein?, New Biol. 2 [2], Seite 197-206.

[104] Petit-Turcotte, C.; Stohl, S. M.; Beffert, U.; Cohn, J. S.; Aumont, N.; Tremblay, M.; Dea, D.; Yang, L.; Poirier, J. und Shachter, N. S. (2001): Apolipoprotein C-I expression in the brain in Alzheimer's disease, Neurobiol Dis 8 [6], Seite 953-963.

[105] Pirttila, T.; Soininen, H.; Heinonen, O.; Lehtimaki, T.; Bogdanovic, N.; Paljarvi, L.; KOSUNEN, O.; Winblad, B.; Riekkinen, P., Sr.; Wisniewski, H. M. und Mehta, P. D. (1996): Apolipoprotein E (apoE) levels in brains from Alzheimer disease patients and controls, Brain Res. 722 [1-2], Seite 71-77.

[106] Pitas, R. E.; Boyles, J. K.; Lee, S. H.; Foss, D. und Mahley, R. W. (1987): Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins, Biochim.Biophys.Acta 917 [1], Seite 148-161.

[107] Poirier, J. (2000): Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism, Ann N.Y.Acad Sci 92481-90-90.

[108] Poirier, J.; Baccichet, A.; Dea, D. und Gauthier, S. (1993): Cholesterol synthesis and lipoprotein reuptake during synaptic remodelling in hippocampus in adult rats, Neuroscience 55 [1], Seite 81-90.

[109] Poirier, J.; Hess, M.; May, P. C. und Finch, C. E. (1991): Astrocytic apolipoprotein E mRNA and GFAP mRNA in hippocampus after entorhinal cortex lesioning, Brain Res Mol Brain Res 11 [2], Seite 97-106.

[110] Price, D. L.; Tanzi, R. E.; Borchelt, D. R. und Sisodia, S. S. (1998): Alzheimer's disease: genetic studies and transgenic models, Annu.Rev Genet 32, Seite 461-493.

[111] Provost, P. R.; Weech, P. K.; Tremblay, N. M.; Marcel, Y. L. und Rassart, E. (1990): Molecular characterization and differential mRNA tissue distribution of rabbit apolipoprotein D, J.Lipid Res. 31 [11], Seite 2057-2065.

[112] Ramassamy, C.; Averill, D.; Beffert, U.; Bastianetto, S.; Theroux, L.; Lussier-Cacan, S.; Cohn, J. S.; Christen, Y.; Davignon, J.; Quirion, R. und Poirier, J. (1999): Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype, Free Radic.Biol Med 27 [5-6], Seite 544-553.

[113] Ramassamy, C.; Averill, D.; Bffert, U.; Theroux, L.; Lussier-Cacan-S.; Cohn, J. S. und Christen, Y. (2000): Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain, Neurobiol Dis 7, Seite 23-37.

[114] Rebeck, G. W.; Reiter, J. S.; Strickland, D. K. und Hyman, B. T. (1993): Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions, Neuron 11 [4], Seite 575-580.

[115] Reindl, M.; Knipping, G.; Wicher, I.; Dilitz, E.; Egg, R.; Deisenhammer, F und Berger, T. (2001): Increased intrathecal production of apolipoprotein D in multiple sclerosis, J Neuroimmunol. 119 [2], Seite 327-332.

[116] Richey, P. L.; Siedlak, S. L.; Smith, M. A. und Perry, G. (1995): Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis, Biochem.Biophys.Res.Commun. 208 [2], Seite 657-663.

[117] Rocchi, A.; Pellegrini, S.; Siciliano, G. und Murri, L. (2003): Causative and susceptibility genes for Alzheimer's disease: a review, Brain Res Bull 61, Seite 1-24.

[118] Rosen, V. M.; Bergeson, J. L.; Putnam, K.; Harwell, A. und Sunderland, T. (2002): Working memory and apolipoprotein E: what's the connection?, Neuropsychologia 40 [13], Seite 2226-2233.

[119] Rubinsztein, D. C. und Easton, D. F. (1999): Apolipoprotein E genetic variation and Alzheimer's disease. a meta-analysis, Dement Geriatr Cogn Disord 10 [3], Seite 199-209.

[120] Russo, C.; Angelini, G.; Dapino, D.; Piccini, A.; Piombo, G.; Schettini, G.; Chen, S.; Teller, J. K.; Zaccheo, D.; Gambetti, P. und Tabaton, M. (1998): Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease, Proc.Natl.Acad.Sci.U.S.A. 95/26 [15598- 15602].

[121] Samatovicz, R. A. (2000): Genetics and brain injury: apolipoprotein E, J.Head Trauma Rehabil. 15 [3], Seite 869-874.

[122] Sasaki, N.; Fukatsu, R.; Tsuzuki, K.; Hayashi, Y.; Yoshida, T.; Fujii, N.; Koike, T.; Wakayama, I.; Yanagihara, R.; Garruto, R.; Amano, N. und Makita, Z. (1998): Advanced glycation end products in Alzheimer's disease and other neurodegenerative diseases, Am J Pathol 153 [4], Seite 1149-1155.

[123] Saunders, A. M. (2000): Apolipoprotein E and Alzheimer disease: an update on genetic and functional analyses, J Neuropathol Exp Neurol 59 [9], Seite 751-758.

[124] Saunders, A. M.; Strittmatter, W. J.; Schmechel, D.; St.George-Hyslop, P. H.; Pericak Vance, M. A.; Joo, S. H.; Rosi, B. L.; Gusella, J. F.; Crapper-MacLachlan, D. R.; Alberts, M. J.; Hulette, C.; Crain, B.; Goldgaber, D. und Roses, A. D. (1993): Association of apolipoprotein E allele epsilon-4 with late-onset familial and sporadic Alzheimer's disease., Neurology. 43 [8], Seite 1467-1472.

[125] Scharnagl H.; Tisljar U.; Winkler K.; Hüttinger M.; Nauck M.A.; Gross W.; Wieland H.; Ohm T.G. und März W. (1999): The A4 amyloid peptide enhances the uptake of beta-very low density lipoproteins by the low density lipoprotein receptor-related protein/alpha2-macroglobulin receptor and heparan sulfate proteoglycans pathway, Laboratory Investigation 79 [10], Seite 1271-1286.

[126] Schindler, P. A.; Settineri, C. A.; Collet, X.; Fielding, C. J. und Burlingame, A. L. (1995): Site-specific detection and structural characterization of the glycosylation of human plasma proteins lecithin:cholesterol acyltransferase and apolipoprotein D using HPLC/electrospray mass spectrometry and sequential glycosidase digestion, Protein Sci. 4 [4], Seite 791-803.

[127] Schmechel, D. E.; Saunders, A. M.; Strittmatter, W. J.; Crain, B. J.; Hulette, C. M.; Joo, S. H.; Pericak Vance, M. A.; Goldgaber, D. und Roses, A. D. (1993): Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease, Proc.Natl.Acad.Sci.U.S.A. 90 [20], Seite 9649-9653.

[128] Schwab, C.; Steele, J. C.; Akiyama, H. und Mcgeer, P. L. (1996): Distinct distribution of apolipoprotein E and beta-amyloid immunoreactivity in the hippocampus of Parkinson dementia complex of Guam, Acta Neuropathol (Berl) 92 [4], Seite 378-385.

[129] Shao, Y.; Gearing, M. und Mirra, S. S. (1997): Astrocyte-apolipoprotein E associations in senile plaques in Alzheimer disease and vascular lesions: a regional immunohistochemical study, J.Neuropathol.Exp.Neurol. 56 [4], Seite 376-381.

[130] Smith, M. A.; Joseph, J. A. und Perry, G. (2000): Tracking the culprit in Alzheimer's disease, Ann NY Acad Sci 924, Seite 35-38.

[131] Smith, M. A.; Kutty, R. K.; Richey, P. L.; Yan, S. D.; Stern, D.; Chader, G. J.; Wiggert, B.; Petersen, R. B. und Perry, G. (1994): Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease, Am.J Pathol. 145 [1], Seite 42-47.

[132] Spreyer, P.; Schaal, H.; Kuhn, G.; Rothe, T.; Unterbeck, A.; Olek, K. und Muller, H. W. (1990): Regeneration-associated high level expression of apolipoprotein D mRNA in endoneurial fibroblasts of peripheral nerve, EMBO J. 9 [8], Seite 2479-2484.

[133] Strittmatter, W. J.; Saunders, A. M.; Goedert, M.; Weisgraber, K. H.; Dong, L. M.; Jakes, R.; Huang, D. Y.; Pericak Vance, M.; Schmechel, D. und Roses, A. D. (1994): Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease, Proc.Natl.Acad.Sci.U.S.A. 91 [23], Seite 11183-11186.

[134] Strittmatter, W. J.; Saunders, A. M.; Schmechel, D.; Pericak Vance, M.; Enghild, J.; Salvesen, G. S. und Roses, A. D. (1993): Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease, Proc.Natl.Acad.Sci.U.S.A. 90 [5], Seite 1977-1981.

[135] Strittmatter, W. J.; Weisgraber, K. H.; Huang, D. Y.; Dong, L. M.; Salvesen, G. S.; Pericak Vance, M.; Schmechel, D.; Saunders, A. M.; Goldgaber, D. und Roses, A. D. (1993): Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease, Proc.Natl.Acad.Sci.U.S.A. 90 [17], Seite 8098-8102.

[136] Sun, Q.; Disher, M. J.; Rustad, T.; Telian, S. A. und Andrews, P. C. (1998): AP30, a differential protein marker for perilymph and cerebrospinal fluid in middle ear fluid, has been purified and identified as human apolipoprotein D, Biochim.Biophys.Acta 1384 [2], Seite 405-413.

[137] Tamaoka, A.; Miyatake, F.; Matsuno, S.; Ishii, K.; Nagase, S.; Sahara, N.; Ono, S.; Mori, H.; Wakabayashi, K.; Tsuji, S.; Takabashi, H. und Shoji, S. (2000): Apolipoprotein E allele-dependent antioxidant activity in brains with Alzheimer's disease, Neurol 54 [12], Seite 2319-2321.

[138] Terrisse, L.; Poirier, J.; Bertrand, P.; Merched, A.; Visvikis, S.; Siest, G; Milne, R. und Rassart, E. (1998): Increased levels of apolipoprotein D in cerebrospinal fluid and hippocampus of Alzheimer's patients, J.Neurochem. 71 [4], Seite 1643-1650.

[139] Terrisse, L.; Seguin, D.; Bertrand, P.; Poirier, J.; Milne, R. und Rassart, E. (1999): Modulation of apolipoprotein D and apolipoprotein E expression in rat hippocampus after entorhinal cortex lesion, Brain Res.Mol.Brain Res. 70 [1], Seite 26-35.

[140] Thomas, E. A.; Dean, B.; Pavey, G. und Sutcliffe, J. G. (2001): Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders, Proc Natl Acad Sci U.S.A 98 [7], Seite 4066-4071.

[141] Thomas, E. A.; Laws, S. M.; Sutcliffe, J. G.; Harper, C.; Dean, B.; McClean, C.; Masters, C.; Lautenschläger, N. und Gandy.S.E.and Martins, R. N. (2003): Apolipoprotein D levels are elevated in prefrontal cortex of subjects with Alzheimer's disease: no relation to apolipoprotein E expression or genotype, Biol Psychiatry 54, Seite 136-141.

[142] Thomas, E. A.; Sautkulis, L. N.; Criado, J. R.; Games, D. und Sutcliffe, J. G. (2001): Apolipoprotein D mRNA expression is elevated in PDAPP transgenic mice, J Neurochem 79 [5], Seite 1059-1064.

[143] Tokuda, T.; Calero, M.; Matsubara, E.; Vidal, R.; Kumar, A.; Permanne, B.; Zlokovic, B.; Smith, J. D.; LaDu, M. J.; Rostagno, A.; Frangione, B. und Ghiso, J. (2000): Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides, Biochem.J. 348 Pt 2, Seite 359-365.

[144] Tolar, M.; Keller, J. N.; Chan, S.; Mattson, M. P.; Marques, M. A. und Crutcher, K. A. (1999): Truncated apolipoprotein E (ApoE) causes increased intracellular calcium and may mediate ApoE neurotoxicity, J.Neurosci. 19 [16], Seite 7100-7110.

[145] Tolar, M.; Marques, M. A.; Harmony, J. A. K. und Crutcher, K. A. (1997): Neurotoxicity of the 22 kDa thrombin-cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated., Journal of Neuroscience. 17 [15], Seite 5678-5686.

[146] Trieu, V. N. und Uckun, F. M. (2000): Apolipoprotein E and apolipoprotein D expression in a murine model of singlet oxygen-induced cerebral stroke, Biochem Biophys.Res Commun. 268 [3], Seite 835-841.

[147] Uchihara, T.; Duyckaerts, C.; He, Y.; Kobayashi, K.; Seilhean, D.; Amouyel, P und Hauw, J. J. (1995): ApoE immunoreactivity and microglial cells in Alzheimer's disease brain, Neurosci.Lett. 195 [1], Seite 5-8.

[148] Vassar, R. und Citron, M. (2001): A beta-generating enzymes: recent advances in beta- and gamma-secretase research, Neuron 27, Seite 419-422.

[149] Vogt, M. und Skerra, A. (2001): Bacterially produced apolipoprotein D binds progesterone and arachidonic acid, but not bilirubin or E-3M2H, J Mol.Recognit. 14 [1], Seite 79-86.

[150] Wang, X. S. und Gruenstein, E. (1997): Rapid elevation of neuronal cytoplasmic calcium by apolipoprotein E peptide, J.Cell Physiol. 173 [1], Seite 73-83.

[151] Warwick-Daw, E.; Payami, H.; Nemens, E. J.; Nochlin, D.; Bird, T. D.; Schellenberg, G. D. und Wijsman, E. M. (2000): The number of trait loci in late-onset Alzheimer disease, Am J Hum.Genet 66 [1], Seite 196-204.

[152] Weaver, C. L.; Espinoza, M.; Kress, V. und Davies, P. (2000): Conformational change as one of the earliest alterations of tau in Alzheimer's disease, Neurobiol Aging 21, Seite 719-727.

[153] Weisgraber, K. H. (1994): Apolipoprotein E: structure-function relationships, Adv.Protein Chem. 45, Seite 249-302.

[154] Weisgraber, K. H. (1990): Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112, J.Lipid Res. 31 [8], Seite 1503-1511.

[155] Weisgraber, K. H.; Roses, A. D. und Strittmatter, W. J. (1994): The role of apolipoprotein E in the nervous system, Curr.Opin.Lipidol. 5 [2], Seite 110-116.

[156] White, F.; Nicoll, J. A. R. und and Horsburgh, K. (2001): Alterations in ApoE and ApoJ in relation to degeneration and regeneration in a mouse model of entorhinal cortex lesion, Exp Neurol 169, Seite 307-318.

[157] Wilson, R. S.; Bienias, J. L.; Berry-Kravis, E.; Evans, D. A. und Bennett, D. A. (2002): The apolipoprotein E epsilon 2 allele and decline in episodic memory, J Neurol Neurosurg Psychiatry 73 [6], Seite 672-677.

[158] Wisniewski, T. und Frangione, B. (1992): Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid, Neurosci.Lett. 135 [2], Seite 235-238.

[159] Xu, P. T.; Gilbert, J. R.; Qiu, H. L.; Ervin, J.; Rothrock Christian, T. R.; Hulette, C. und Schmechel, D. E. (1999): Specific regional transcription of apolipoprotein E in human brain neurons, Am.J.Pathol. 154 [2], Seite 601-611.

[160] Yamada, T.; Kondo, A.; Takamatsu, J.-I.; Tateishi, J. und Goto, I. (1995): Apolipoprotein E mRNA in the brains of patients with Alzheimer's disease, J Neurol Sci 129, Seite 56-61.

[161] Yamaguchi, H.; Ishiguro, K.; Sugihara, S.; Nakazato, Y.; Kawarabayashi, T; Sun, X. und Hirai, S. (1994): Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition, Acta Neuropathol (Berl) 88 [5], Seite 413-419.

[162] Zannis, V. I. und Breslow, J. L. (1981): Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification, Biochemistry 20 [4], Seite 1033-1041.

[163] Zarow, C. und Victoroff, J. (1998): Increased apolipoprotein E mRNA in the hippocampus in Alzheimer disease and in rats after entorhinal cortex lesioning, Exp Neurol 149 [1], Seite 79-86.

[164] Zeng, C.; Spielman, A. I.; Vowels, B. R.; Leyden, J. J.; Biemann, K. und Preti, G. (1996): A human axillary odorant is carried by apolipoprotein D, Proc Natl Acad Sci U.S.A 93 [13], Seite 6626-6630.